The Diagnostic Power of Circulating miR-1246 in Screening Cancer: An Updated Meta-analysis

Table 2

Subgroup meta-analyses for sensitivity, specificity, and DOR.

Variable	Number of study	Number of case	Sensitivity				Specificity				DOR
			Estimates, % (95% CI)	, %			Estimates, % (95% CI)	, %			Estimates, % (95% CI)	, %
Cancer type						0.106				<0.001				<0.001
BC	7	3321	91.8 (83.9-95.9)	70.6	0.001		90.4 (84.9-94.0)	73.5	<0.001		98.5 (72.2-134.2)	29.4	0.194
CRC	4	483	89.5 (55.2-98.3)	86.3	<0.001		87.1 (67.4-95.7)	73.3	0.011		47.6 (5.6-401.3)	87.1	<0.001
ESCC	3	620	78.3 (70.2-84.6)	67.1	0.016		68.0 (61.6-73.9)	0.0	0.776		8.0 (5.4-11.8)	0.0	0.588
HCC	4	328	77.1 (65.5-85.6)	67.4	0.027		87.5 (78.1-93.3)	0.0	0.751		18.6 (9.7-35.5)	29.7	0.234
PC	3	301	84.7 (78.6-89.3)	61.9	0.072		68.0 (59.3-75.6)	0.2	0.367		12.3 (5.6-26.9)	30.2	0.239
Others^†	8	861	80.3 (72.6-86.3)	74.0	<0.001		89.5 (77.9-95.3)	46.4	0.061		27.5 (10.3-73.5)	75.9	<0.001
Control type						0.292				<0.001				0.068
HC	26	5552	84.8 (79.7-88.8)	82.9	<0.001		86.5 (81.6-90.3)	82.9	<0.001		31.5 (19.1-52.1)	87.2	<0.001
Benign	3	362	77.8 (61.5-88.5)	83.4	0.002		68.2 (60.9-74.6)	50.8	0.131		8.6 (2.3-31.7)	77.8	0.011
Sample type						0.479				0.049				0.008
Plasma	9	544	89.1 (77.9-94.9)	64.4	0.004		92.0 (85.8-95.7)	0.0	0.716		85.8 (30.1-244.0)	50.5	0.040
Serum	19	5101	82.5 (76.4-87.3)	87.4	<0.001		82.7 (77.1-87.1)	88.4	<0.001		21.3 (12.2-37.3)	91.8	<0.001
Others	2	269	85.2 (78.2-90.3)	56.0	0.103		76.8 (43.0-93.6)	0.0	0.917		12.5 (6.7-23.5)	0.0	0.520
Sample size						0.613				0.004				0.048
≥100	14	1039	85.7 (77.0-91.5)	65.3	<0.001		79.3 (73.0-84.5)	91.9	<0.001		18.8 (10.2-34.5)	93.6	<0.001
<100	15	4875	83.3 (77.4-87.9)	88.4	<0.001		91.9 (85.5-89.2)	23.3	0.185		50.3 (23.4-108.2)	59.2	0.001
Technique						0.009				<0.001				<0.001
RT-qPCR	23	2995	81.7 (76.3-86.2)	79.2	<0.001		82.5 (77.1-86.9)	53.0	<0.001		19.7 (12.4-31.3)	75.9	<0.001
Others	6	2919	92.6 (86.1-96.2)	16.2	0.310		93.4 (92.0-94.5)	0.0	0.598		109.5 (83.9-142.9)	4.3	0.389
Data extraction						<0.001				0.016				0.675
Direct	21	5420	86.9 (82.2-90.5)	82.1	<0.001		82.2 (76.7-86.6)	87.9	<0.001		28.6 (16.1-50.8)	90.8	<0.001
Indirect	8	494	71.2 (61.4-79.4)	55.7	0.027		92.6 (85.7-96.3)	0.0	0.642		23.1 (10.2-52.3)	37.6	0.129

BC: breast cancer; CRC: colorectal cancer; DOR: diagnostic odds ratio; ESCC: esophageal squamous cell carcinoma; HC: healthy control; HCC: hepatocellular carcinoma; PC: pancreatic cancer; PCa: prostate cancer; RT-qPCR: reverse transcriptase quantitative polymerase chain reaction; 95% CI: 95% confidence interval. Significance for heterogeneity; significance between subgroups; ^†including gallbladder cancer (), gastric cancer (), melanoma (), multiple myeloma (), non-small-cell lung cancer (), ovarian cancer (), prostate cancer (), and pancreatobiliary tract cancer ().